Preventing angle closure glaucoma in Caucasian patients
Danish Angle Closure Prevention Trial
This study tests if a laser treatment can help prevent angle closure glaucoma from getting worse in Caucasian patients who are at risk.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 242 (estimated) |
| Ages | 40 Years to 80 Years |
| Sex | All |
| Sponsor | University of Aarhus Academic / other |
| Locations | 5 sites (Aalborg and 4 other locations) |
| Trial ID | NCT06077253 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of prophylactic laser iridotomy in preventing the progression of primary angle closure suspects (PACS) in a Caucasian population. It employs a prospective, randomized paired-eye design, where one eye receives the laser treatment while the other is observed over a five-year follow-up period. The study will assess the outcomes based on the development of angle closure glaucoma and other related complications.
Who should consider this trial
Good fit: Ideal candidates for this study are Caucasian individuals identified as primary angle closure suspects with specific clinical criteria.
Not a fit: Patients with previous eye surgeries, existing glaucoma, or other significant ocular conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a preventive treatment option for patients at risk of developing angle closure glaucoma.
How similar studies have performed: Other studies have shown promising results with laser iridotomy in similar populations, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Primary angle closure suspect: ≥180 degrees (cumulative) irido-trabecular contact on darkroom gonioscopy, IOP\<21mmHg, no peripheral anterior synechiae, no glaucomatous optic neuropathy * Best-corrected visual acuity (BCVA) \>0.8 on both eyes * Caucasian Exclusion Criteria: * Pseudophakia * Previous iridotomy * Clinically significant cataract with indication for surgery, * Gaucoma * Uveitis * Unstable retinal conditions * Ocular malignancies * PEX * PDS * Systemic or ocular corticosteroid treatment
Where this trial is running
Aalborg and 4 other locations
- Aalborg University Hospital — Aalborg, Denmark (Recruiting)
- Aarhus University Hospital — Aarhus, Denmark (Recruiting)
- Rigshospitalet Glostrup — Glostrup Municipality, Denmark (Recruiting)
- Odense University Hospital — Odense, Denmark (Not_yet_recruiting)
- Sygehus Lillebælt — Vejle, Denmark (Recruiting)
Study contacts
- Principal investigator: Niklas Telinius — Aarhus University Hospital
- Study coordinator: Niklas Telinius, PhD, DMSc
- Email: telinius@me.com
- Phone: +4530238533
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.